An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cabazitaxel (Primary) ; Carboplatin; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2020 Status changed from active, no longer recruiting to completed.
- 09 Sep 2019 Results published in the Lancet Oncology
- 24 Oct 2018 Planned End Date changed from 1 Jul 2030 to 11 Jul 2030.